Cooperative Agreement R01CA138401

This $443,354 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate targeting the hexosamine biosynthetic pathway as a potential treatment for pediatric brain tumors. The research aims to understand how this metabolic pathway supports the growth and apoptosis resistance of diffuse midline gliomas with the...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research on a novel signaling axis involving the protein connexin 43 (CX43) and its role in regulating cancer stem cells in glioblastoma, the most common and deadly form of brain cancer. The $161,000 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve...

This Project Grant award, valued at $611,591.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to research new strategies to overcome therapy resistance in Hedgehog pathway-driven medulloblastoma, the most common malignant pediatric brain cancer. The key focus areas of this research project include: 1) investigating a new...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...

This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $402,401 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to evaluate the role of SPAK and OSR1 kinases in glioblastoma (GBM) chemotherapy resistance. The 2-year project, running from July 2024 to June 2026, aims to assess if these stress-sensing kinases serve as a resistance mechanism to standard-of-care chemoradiotherapy for GBM, the most deadly brain cancer. The research...

This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...

This federal Project Grant award of $131,360 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research at the University of New Haven to characterize the long non-coding RNA GIHCG and assess its potential as a therapeutic target for glioblastoma, the most aggressive form of brain cancer. The 4-year project aims to use CRISPR/Cas9 gene editing to...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $155,348 to The Trustees of the University of Pennsylvania (UEI: GM1XX56LEP58) to conduct research on the role of astrocytes in spinal cord injury and regeneration. The key objectives of this 2.5-year project are to define the dynamic behavior of astrocytes induced by neuronal injury in vivo using...

This Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on developing novel therapeutic approaches to treat neuroblastoma, the most common extracranial solid pediatric cancer and a leading cause of cancer-related deaths in children. The $690,013 award to Pennsylvania State University's Milton S. Hershey Medical Center aims to target the role of extracellular vesicles (EVs) in neuroblastoma progression and metastasis. Specifically, the...

This $638,697 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate the role of the SMARCA5 protein in the development and progression of glioblastoma, an aggressive type of brain cancer. The goal of the research is...